• 1. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 2. An atmosphere and light tuned highly diastereoselective synthesis of cyclobuta/penta[b]indoles from aniline-tethered alkylidenecyclopropanes with alkynes?
  Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
• 3. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 4. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Introduction to Methyl 1-(2-Methoxyethyl)-1H-Pyrazole-3-Carboxylate (CAS No. 1172825-92-1)

Methyl 1-(2-Methoxyethyl)-1H-pyrazole-3-Carboxylate (CAS No. 1172825-92-1) is a specialized organic compound that has garnered significant attention in the field of pharmaceutical research and chemical synthesis. This compound, characterized by its pyrazole core structure functionalized with a methoxyethyl group and a carboxylate moiety, exhibits unique chemical properties that make it a valuable intermediate in the development of various bioactive molecules.

The pyrazole scaffold is a prominent heterocyclic system widely recognized for its versatility in medicinal chemistry. Pyrazole derivatives have been extensively studied due to their broad spectrum of biological activities, including anti-inflammatory, antimicrobial, and anticancer properties. The introduction of the Methoxyethyl group at the 1-position and the Carboxylate group at the 3-position further enhances the compound's potential as a pharmacophore, enabling diverse interactions with biological targets.

In recent years, there has been a surge in research focused on developing novel pyrazole-based drugs. The structural features of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate make it an attractive candidate for further exploration in drug discovery. Its ability to modulate enzyme activity and interact with specific binding sites has been highlighted in several preclinical studies. These studies suggest that derivatives of this compound may have therapeutic applications in conditions such as chronic inflammation and neurodegenerative diseases.

The synthesis of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate involves multi-step organic reactions that require precise control over reaction conditions. The incorporation of the methoxyethyl group and the carboxylate functionality necessitates careful selection of reagents and catalysts to ensure high yield and purity. Advanced synthetic techniques, such as palladium-catalyzed cross-coupling reactions, have been employed to achieve optimal results. These methods not only enhance efficiency but also minimize byproduct formation, making the process more sustainable.

The chemical stability of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate is another critical factor that influences its utility in pharmaceutical applications. The compound's stability under various storage conditions has been thoroughly evaluated, demonstrating its suitability for long-term use in research laboratories and industrial settings. Additionally, its solubility profile in common organic solvents makes it amenable to formulation into various drug delivery systems.

Recent advancements in computational chemistry have facilitated the design of more effective derivatives of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate. Molecular modeling studies have identified key structural motifs that can enhance binding affinity and selectivity towards target proteins. These insights have guided the development of novel analogs with improved pharmacokinetic properties. Such computational approaches are integral to modern drug discovery pipelines, enabling researchers to predict and optimize molecular interactions with high precision.

The biological activity of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate has been investigated through both in vitro and in vivo assays. In vitro studies have revealed its potential as an inhibitor of several enzymes implicated in disease pathways. For instance, preliminary data suggest that this compound may suppress the activity of cyclooxygenase-2 (COX-2), a key enzyme involved in inflammation. Similarly, its interaction with other enzymes such as kinases and proteases has been explored, highlighting its broad therapeutic potential.

In vivo studies have further validated the biological relevance of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate. Animal models have demonstrated its ability to modulate inflammatory responses and slow down disease progression in conditions like rheumatoid arthritis. These findings are particularly encouraging given the limitations associated with existing treatments for chronic inflammatory disorders. The compound's favorable pharmacokinetic profile, including good oral bioavailability and rapid tissue distribution, supports its further development as a therapeutic agent.

The safety profile of Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate is another area of active investigation. Toxicological assessments have been conducted to evaluate potential adverse effects at various exposure levels. These studies have shown that the compound is well-tolerated at therapeutic doses, with minimal systemic toxicity observed. However, further research is needed to fully characterize its long-term safety implications.

The future prospects for Methyl 1-(2-methoxyethyl)-1H-pyrazole-3-carboxylate are promising, with ongoing research aimed at expanding its applications in drug development. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of laboratory findings into clinical trials. The compound's unique structural features and demonstrated biological activity position it as a valuable asset in the quest for novel therapeutics.

• 1170089-42-5(3-(Methoxycarbonyl)-1H-pyrazol-1-ylacetic Acid)
• 936249-32-0(1-(2-methoxyethyl)-1H-Pyrazole-3-carboxylic acid)
• 50920-45-1(ethyl 1-ethyl-5-methyl-1H-pyrazole-3-carboxylate)
• 88398-71-4(Methyl 1-Ethyl-5-methyl-pyrazole-3-carboxylate)
• 1006348-65-7(methyl 1-isopropyl-1H-pyrazole-3-carboxylate)
• 1007503-15-2(Ethyl 1-ethyl-1H-pyrazole-3-carboxylate)
• 89943-27-1(Methyl 1-Ethyl-1H-pyrazole-3-carboxylate)
• 1006319-54-5(methyl 1-(2-ethoxy-2-oxoethyl)-1H-pyrazole-3-carboxylate)
• 1171028-49-1(methyl 1-propyl-1H-pyrazole-3-carboxylate)
• 88398-73-6(Methyl 1-ethyl-3-methyl-1H-pyrazole-5-carboxylate)